Index of Published Newsletters
On this page
For articles that are no longer available online, contact the Health Product InfoWatch Editorial Team.
The Health Product InfoWatch
November 2024
- Monthly recap of health product safety information
- New health product safety information
- Scope
- Reporting Adverse Reactions
- Helpful links
- Contact us
- References
October 2024
- Announcement
- Monthly recap of health product safety information
- New health product safety information
- Scope
- Reporting Adverse Reactions
- Helpful links
- Contact us
- References
September 2024
- Announcement
- Monthly recap of health product safety information
- ACH-Sitagliptin
- Breast implants
- Epinephrine Injection USP, 1 mg/10 mL single-use syringes
- Health First Ashwagandha Supreme capsules
- JAMP Digoxin
- JAMP-Mycophenolate
- Ratio-Ectosone (TEVA-Ectosone) 0.1% regular lotion and 0.05% mild lotion
- Sensorcaine with Epinephrine (bupivacaine hydrochloride, 5 mg/mL and epinephrine (epinephrine bitartrate), 5 mcg/mL)
- Sodium-glucose cotransporter-2 (SGLT2) inhibitors (canagliflozin, dapagliflozin, empagliflozin)
- Unauthorized Health Products
- New health product safety information
August 2024
- Monthly recap of health product safety information
- New health product safety information
- Safety brief
- Product monograph updates
- Clavulin (amoxicillin and clavulanate potassium) and other amoxicillin-containing products
- Retevmo (selpercatinib)
- Sodium-glucose cotransporter-2 (SGLT2) inhibitors: Invokana (canagliflozin), Invokamet (canagliflozin/metformin), Forxiga (dapagliflozin), Xigduo (dapagliflozin/metformin), Jardiance (empagliflozin) and Synjardy (empagliflozin/metformin)
- Scope
- Reporting Adverse Reactions
- Helpful links
- Contact us
- References
July 2024
- Monthly recap of health product safety information
- Accel-Ondansetron ODT, Mint-Betahistine and PMS-Pirfenidone
- Albrioza (sodium phenylbutyrate and ursodoxicoltaurine)
- Carbamazepine extended-release tablets
- Dianeal PD4 2.5% dextrose and Physioneal 40 2.27% glucose peritoneal dialysis solutions
- Isotretinoin
- JAMP Digoxin
- Ratio-Ectosone (TEVA-Ectosone) 0.05% mild lotion
- Unauthorized Health Products
- New health product safety information
- Scope
- Reporting Adverse Reactions
- Helpful links
- Contact us
- References
June 2024
- Monthly recap of health product safety information
- New health product safety information
- Scope
- Reporting Adverse Reactions
- Helpful links
- Contact us
- References
May 2024
- Monthly recap of health product safety information
- New health product safety information
- Scope
- Reporting Adverse Reactions
- Helpful links
- Contact us
- References
April 2024
- Health products mentioned in this issue
- Monthly recap of health product safety information
- New health product safety information
- Scope
- Reporting Adverse Reactions
- Helpful links
- Suggestions?
March 2024
- Health products mentioned in this issue
- Announcement
- Monthly recap of health product safety information
- Scope
- Reporting Adverse Reactions
- Helpful links
- Suggestions?
February 2024
- Health products mentioned in this issue
- Monthly recap of health product safety information
- New health product safety information
- Scope
- Reporting Adverse Reactions
- Helpful links
- Suggestions?
January 2024
- Health products mentioned in this issue
- Monthly recap of health product safety information
- New health product safety information
- Scope
- Reporting Adverse Reactions
- Helpful links
- Suggestions?
December 2023
- Health products mentioned in this issue
- Announcement
- Monthly recap of health product safety information
- New health product safety information
- Scope
- Reporting Adverse Reactions
- Helpful links
- Suggestions?
- Copyright
November 2023
- Health products mentioned in this issue
- Monthly recap of health product safety information
- New health product safety information
- Scope
- Reporting Adverse Reactions
- Helpful links
- Suggestions?
- Copyright
October 2023
- Health products mentioned in this issue
- Monthly recap of health product safety information
- New health product safety information
- Scope
- Reporting Adverse Reactions
- Helpful links
- Suggestions?
September 2023
- Health products mentioned in this issue
- Monthly recap of health product safety information
- Online pharmacies: Marketing of drugs and medical devices
- Scope
- Reporting Adverse Reactions
- Helpful links
- Suggestions?
August 2023
- Health products mentioned in this issue
- Monthly recap of health product safety information
- New health product safety information
- Scope
- Reporting Adverse Reactions
- Helpful links
- Suggestions?
- Copyright
July 2023
- Health products mentioned in this issue
- Monthly recap of health product safety information
- New health product safety information
- Scope
- Reporting Adverse Reactions
- Helpful links
- Suggestions?
June 2023
- Health products mentioned in this issue
- Announcement
- Drug and vaccine authorizations and communications for COVID-19
- Monthly recap of health product safety information
- New health product safety information
- Scope
- Reporting Adverse Reactions
- Helpful links
- Suggestions?
- Copyright
May 2023
- Health products mentioned in this issue
- Monthly recap of health product safety information
- New health product safety information
- Scope
- Reporting Adverse Reactions
- Helpful links
- Suggestions?
- Copyright
April 2023
- Health products mentioned in this issue
- Announcement
- Drug and vaccine authorizations and communications for COVID-19
- Monthly recap of health product safety information
- New health product safety information
- Scope
- Reporting Adverse Reactions
- Helpful links
- Suggestions?
- Copyright
March 2023
- Health products mentioned in this issue
- Drug and vaccine authorizations and communications for COVID-19
- Monthly recap of health product safety information
- New health product safety information
- Scope
- Reporting Adverse Reactions
- Helpful links
- Suggestions?
- Copyright
February 2023
- Health products mentioned in this issue
- Did you know?
- Drug and vaccine authorizations and communications for COVID-19
- Announcement
- Monthly recap of health product safety information
- New health product safety information
- Scope
- Reporting Adverse Reactions
- Helpful links
- Suggestions?
- Copyright
January 2023
- Health products mentioned in this issue
- Drug and vaccine authorizations and communications for COVID-19
- Announcement:
- Monthly recap of health product safety information
- New health product safety information
- Scope
- Reporting Adverse Reactions
- Helpful links
- Suggestions?
- Copyright
December 2022
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Drug and vaccine authorizations and communications for COVID-19
- Monthly recap of health product safety information
- New health product safety information
- Scope
- Reporting adverse reactions
- Helpful links
- Suggestions?
- Copyright
November 2022
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Drug and vaccine authorizations and communications for COVID-19
- Monthly recap of health product safety information
- New health product safety information
- Scope
- Reporting adverse reactions
- Helpful links
- Suggestions?
- Copyright
October 2022
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Drug and vaccine authorizations and communications for COVID-19
- Monthly recap of health product safety information
- Scope
- Reporting adverse reactions
- Helpful links
- Suggestions?
- Copyright
September 2022
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Drug and vaccine authorizations and communications for COVID-19
- Monthly recap of health product safety information
- Scope
- Reporting Adverse Reactions
- Helpful links
- Suggestions?
- Copyright
August 2022
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Monthly recap of health product safety information
- New health product safety information
- Scope
- Reporting Adverse Reactions
- Helpful links
- Suggestions?
- Copyright
July 2022
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Drug and vaccine authorizations and communications for COVID-19
- Announcement:
- Monthly recap of health product safety information
- New health product safety information
- Scope
- Reporting Adverse Reactions
June 2022
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Drug and vaccine authorizations and communications for COVID-19
- Announcements:
- Monthly recap of health product safety information
- New health product safety information
- Scope
- Reporting Adverse Reactions
May 2022
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Drug and vaccine authorizations and communications for COVID-19
- Monthly recap of health product safety information
- Scope
- Reporting Adverse Reactions
- Helpful links
- Suggestions?
- Copyright
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Drug and vaccine authorizations and communications for COVID-19
- Monthly recap of health product safety information
- Scope
- Reporting Adverse Reactions
- Helpful links
- Suggestions?
- Copyright
April 2022
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Drug and vaccine authorizations and communications for COVID-19
- Announcements:
- Monthly recap of health product safety information
- New health product safety information
- Scope
- Reporting Adverse Reactions
- Helpful links
- Suggestions?
- Copyright
March 2022
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Drug and vaccine authorizations and communications for COVID-19
- Monthly recap of health product safety information
- New health product safety information
- Scope
- Reporting Adverse Reactions
- Helpful links
- Suggestions?
- Copyright
February 2022
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Drug and vaccine authorizations and communications for COVID-19
- Announcement
- Monthly recap of health product safety information
- Health Canada News
- Scope
- Reporting Adverse Reactions
- Helpful links
- Suggestions?
- Copyright
January 2022
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Drug and vaccine authorizations and communications for COVID-19
- Announcements
- Monthly recap of health product safety information
- New health product safety information
- Scope
- Reporting Adverse Reactions
- Helpful links
- Suggestions?
- Copyright
December 2021
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Monthly recap of health product safety information
- New health product safety information
- Review article: Atypical hemolytic reactions following exposure to gemtuzumab ozogamicin (Mylotarg)
- Product monograph update: Lupron and Lupron Depot (leuprolide acetate)
- Product monograph update: Selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs)
- Lucentis (ranibizumab injection): Authorization with conditions
- Scope
- Reporting adverse reactions
- Helpful links
- Suggestions
- Copyright
November 2021
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Drug and vaccine authorizations and communications for COVID-19
- Monthly recap
- New information
- Scope
- Helpful links
- Suggestions?
- Copyright
October 2021
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Monthly recap
- New information
- Vaccine safety biannual summary: Summary for January 1, 2020 to June 30, 2020
- Product monograph update: CellCept (mycophenolate mofetil)
- Product monograph update: Zyloprim (allopurinol)
- Notice of market authorization with conditions: Lumakras (sotorasib)
- Notice of market authorization with conditions: Pemazyre (pemigatinib)
- Notice of market authorization with conditions: Truseltiq (infigratinib)
- Notice of market authorization with conditions: Zepzelca (lurbinectedin)
- Scope
- Helpful links
- Suggestions?
- Copyright
September 2021
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Drug and vaccine authorizations and communications for COVID-19
- Monthly recap
- New information
- Scope
- Helpful links
- Suggestions?
- Copyright
August 2021
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Drug and vaccine authorizations and communications for COVID-19
- Product monograph updates for COVID-19 vaccines
- Monthly recap
- Scope
- Helpful links
- Suggestions?
- Copyright
July 2021
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Drug and vaccine authorizations and communications for COVID-19
- Monthly recap
- New information
- Scope
- Helpful links
- Suggestions?
- Copyright
June 2021
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Drug and vaccine authorizations and communications for COVID-19
- Monthly recap
- New information
- Scope
- Helpful links
- Suggestions
- Copyright
May 2021
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Drug and vaccine authorizations and communications for COVID-19
- Monthly recap
- New information
- Did you know
- Scope
- Helpful links
- Suggestions?
- Copyright
April 2021
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Drug and vaccine authorizations and communications for COVID-19
- Announcement: Talc and the risk to human health
- Monthly recap
- New information
- Scope
- Helpful links
- Suggestions?
- Copyright
March 2021
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Drug and vaccine authorizations for COVID-19
- Monthly recap
- New information
- Scope
- Helpful links
- Suggestions?
- Copyright
February 2021
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Announcement: International Coalition of Medicines Regulatory Authorities statement on the regulation of COVID-19 vaccines for safety and effectiveness
- Drug and vaccine authorizations for COVID-19: Pfizer-BioNTech COVID-19 vaccine
- Monthly recap
- New information
- Scope
- Helpful links
- Suggestions?
- Copyright
January 2021
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Drug and vaccine authorizations for COVID-19
- Monthly recap
- Health Canada News
- Scope
- Helpful links
- Suggestions?
- Copyright
December 2020
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Drug and Vaccine authorizations for COVID-19
- Monthly recap
- New information
- Scope
- Helpful links
- Suggestions?
- Copyright
November 2020
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Monthly recap
- New information
- Scope
- Helpful links
- Suggestions?
- Copyright
October 2020
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Monthly recap
- New information
- Scope
- Helpful links
- Suggestions?
- Copyright
September 2020
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Did you know: Canadian Paediatric Surveillance Program 2019 results
- Monthly recap
- New information
- Scope
- Helpful links
- Suggestions?
- Copyright
August 2020
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Did you know? Cabazitaxel products with different instructions for dilution
- Monthly recap
- New information
- Scope
- Helpful links
- Suggestions?
- Copyright
July 2020
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Did you know? Health Canada's list of authorized antiseptic skin cleansers or hand sanitizers
- Monthly recap
- New information
- Product monograph update: Imbruvica (ibrutinib)
- Product monograph update: Imuran (azathioprine)
- Product monograph update: Rythmol (propafenone hydrochloride)
- Notice of market authorization with conditions: Veklury (remdesivir)
- Notice of market authorization with conditions: Polivy (polatuzumab vedotin)
- Scope
- Helpful links
- Suggestions?
- Copyright
June 2020
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Did you know? List of Drugs for Exceptional Importation and Sale
- Announcement: Statements on vaccine confidence by the International Coalition of Medicines Regulatory Authorities
- Monthly recap
- New information
- Scope
- Helpful links
- Suggestions?
- Copyright
May 2020
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Announcement: Labelling error for WinRho SDF
- Did you know? List of Drugs for Exceptional Importation and Sale
- Monthly recap
- New information
- Scope
- Helpful links
- Suggestions?
- Copyright
April 2020
- Health products mentioned in this issue
- Coronavirus disease (COVID-19)
- Monthly recap
- New information
- Scope
- Helpful links
- Suggestions?
- Copyright
March 2020
- Health products mentioned in this issue
- Announcements:
- Monthly recap
- New information
- Scope
- Helpful links
- Suggestions?
- Copyright
February 2020
- Health products mentioned in this issue
- Announcement
- Monthly recap
- New information
- Scope
- Helpful links
- Suggestions?
- Copyright
January 2020
- Health products mentioned in this issue
- Announcement
- Monthly recap
- New information
- Scope
- Helpful links
- Suggestions?
- Copyright
December 2019
- Health products mentioned in this issue
- Announcement: Mandatory reporting by hospitals, December 16, 2019
- Monthly recap
- New information
- Scope
- Helpful links
- Suggestions?
- Copyright
November 2019
- Health products mentioned in this issue
- Monthly recap
- New information
- Health Canada News: Preparing for Mandatory Reporting
- Scope
- Helpful links
- Suggestions?
- Copyright
October 2019
- Health products mentioned in this issue
- Monthly recap
- New information
- Scope
- Helpful links
- Suggestions?
- Copyright
September 2019
- Health products mentioned in this issue
- Announcement: Mandatory reporting by hospitals begins December 16, 2019
- Announcement: Reporting of pulmonary disease associated with vaping products
- Monthly recap
- Scope
- Helpful links
- Suggestions?
- Copyright
August 2019
- Health products mentioned in this issue
- Announcement: Educational Support for Mandatory Reporting of Serious Adverse Drug Reactions and Medical Device Incidents by Hospitals
- Monthly recap
- New information
- Scope
- Helpful links
- Suggestions?
- Copyright
July 2019
- Health products mentioned in this issue
- Monthly recap
- New information
- Review Article: Hepatotoxicity associated with the use of oral Aloe vera-containing health products
- Product monograph update: Brilinta (ticagrelor)
- Product monograph update: Systemic fluoroquinolones and fluoroquinolone solution for inhalation
- Product monograph update: Trisenox (arsenic trioxide)
- Notice of market authorization with conditions: Vitrakvi (larotrectinib)
- Scope
- Helpful links
- Suggestions?
- Copyright
June 2019
- Health products mentioned in this issue
- Announcement: Health Canada warns Canadians of potential cancer risk associated with non-prescription gentian violet drug products
- Monthly recap
- New information
- Scope
- Helpful links
- Suggestions?
- Copyright
May 2019
- Health products mentioned in this issue
- Announcement: Human-Use Antiseptic Drugs Guidance Document
- Monthly recap
- New information
- Scope
- Reporting Adverse Reactions
- Suggestions?
- Copyright
April 2019
- Health products mentioned in this issue
- Announcement: Impurities found in certain angiotensin II receptor blockers
- Monthly recap
- New information
- Scope
- Helpful links
- Suggestions?
- Copyright
March 2019
- Health products mentioned in this issue
- Announcement - Comparative effectiveness and safety of biosimilar drugs
- Announcement - Program launch: Help Stop Illegal Marketing of Drugs and Devices
- Announcement - Public access to clinical information on drugs and medical devices
- Monthly recap
- New information
February 2019
- Health products mentioned in this issue
- Announcement - Update on Biologics Naming
- Monthly recap
- New information
January 2019
- Announcement - Trelegy Ellipta
- Opioid Updates
- Monthly recap
- New information
- Review article: Prolonged use of hydrochlorothiazide and the risk of non-melanoma skin cancer
- Vaccine safety biannual summary: Report for January 1, 2018 to June 30, 2018
- Product monograph update: Biaxin BID, Biaxin XL, and Biaxin (clarithromycin)
- Product monograph update: Lamictal (lamotrigine)
- Product monograph update: Revlimid (lenalidomide)
December 2018
- Announcement - Annual trends for adverse reaction case reports and medical device incident reports (2008-2017)
- Announcement - Talc and the risk to human health
- Opioid Updates
- Monthly recap
- New information
November 2018
- Monthly recap
- New information
- Review article: Lamotrigine and international reports of hemophagocytic lymphohistiocytosis (HLH)
- Product monograph updates: Kayexalate (sodium polystyrene sulfonate) and Resonium Calcium (calcium polystyrene sulfonate)
- Product monograph update: Rifadin (rifampin)
- Notice of market authorization with conditions: Folotyn (pralatrexate injection)
October 2018
September 2018
- Announcement: Change to medical device audit process impacting product availability
- Announcement: Opioid marketing and advertising - share your stories
- Monthly recap
- New information
August 2018
July 2018
June 2018
May 2018
- Announcement: New regulations to provide better information for patients on the safe use of opioid medications
- Monthly recap
- New information
- Product monograph update: Dipeptidylpeptidase-4 (DPP-4) Inhibitors
- Product monograph update: Elavil (amitriptyline hydrochloride)
- Product monograph update: Gadolinium-Based Contrast Agents
- Product monograph update: Imitrex injection (sumatriptan succinate)
- Product monograph update: Revlimid (lenalidomide)
- Product monograph update: Zydelig (idelalisib)
- Notice of Market Authorization with Conditions: Bavencio (avelumab)
- Notice of Market Authorization with Conditions: Imfinzi (durvalumab)
April 2018
March 2018
February 2018
January 2018
December 2017
November 2017
October 2017
September 2017
August 2017
- Announcement: Recalls and safety alerts mobile application
- Monthly recap
- New information
- Product monograph update: Product monograph update: Invokana (canagliflozin) and Invokamet (canagliflozin and metformin hydrochloride)
- Product monograph update: Revlimid (lenalidomide)
- Product monograph update: Temodal (temozolomide)
- Product monograph update: Videx EC (didanosine)
- Product monograph update: Zelboraf (vemurafenib)
- Vaccine safety quarterly summary: Report for October 1, 2016 to December 31, 2016
July 2017
June 2017
May 2017
April 2017
- Monthly recap
- New information
- Product monograph update: Amiodarone (intravenous)
- Product monograph update: Primaquine (primaquine phosphate)
- Product monograph update: Seroquel (quetiapine fumarate) and Seroquel XR (quetiapine fumarate extended-release)
- Product monograph update: Tecfidera (dimethyl fumarate)
- Product monograph update: Valproate products (valproic acid, divalproex sodium)
March 2017
February 2017
- Announcement
- Monthly recap
- New information
- Review article: Colorectal stents and bevacizumab: increased risk of intestinal perforation
- Vaccine safety quarterly summary: Report for April 1, 2016 to June 30, 2016
- Product monograph update: Tramadol-containing products
- Product monograph update: Votrient (pazopanib)
- Product monograph update: Zyprexa (olanzapine)
January 2017
December 2016
November 2016
October 2016
- Announcement
- Monthly recap
- New information
- Case report: Green Tea Triple Fat Burner - risk of drug-induced liver injury
- Product monograph update: Aczone (dapsone topical gel 5%)
- Product monograph update: Edarbyclor (azilsartan medoxomil and chlorthalidone)
- Product monograph update: Ferrlecit (sodium ferric gluconate complex in sucrose injection)
- Product monograph update: Intuniv XR (guanfacine)
- Product monograph update: Pomalyst (pomalidomide)
- Product monograph update: Solu-Medrol (methylprednisolone sodium succinate) Act-O-Vial 40 mg
September 2016
August 2016
July 2016
June 2016
May 2016
April 2016
March 2016
February 2016
- Monthly recap
- New information
- Review article: Pseudoephedrine and ischemic colitis
- Product confusion alert: Risk of eye injury with improper use of hydrogen peroxide-based contact lens solutions
- Vaccine safety review: Report for April 1, 2015 to June 30, 2015
- Product Monograph Updates: Piperacillin/Tazobactam for Injection and Piperacillin for Injection
January 2016
November 2015
- Monthly recap
- Case report: International case of respiratory depression in a child with ultrarapid CYP2D6 metabolism after tramadol use
- Product confusion alert: Health product name confusion: Bio-K Plus and Bio K 20 Potassium
- Vaccine safety review: Report for January 1, 2015 to March 31, 2015
- Product monograph and medical device instructions for use updates: Hormonal and non-hormonal intrauterine systems/devices
September 2015
July 2015
June 2015
May 2015
March 2015
January 2015
Canadian Adverse Reaction Newsletters
October 2014; 24(4)
- Incretin-based therapies and the risk of pancreatic cancer
- Intravenous methylprednisolone and liver injury
- Sorafenib and osteonecrosis of the jaw
- Summary of advisories
July 2014; 24(3)
- Cisplatin and aortic thrombosis
- Hydroxychloroquine and hypoglycemia
- Case presentation: Suspected interaction between ginkgo biloba and efavirenz
- Summary of advisories
April 2014; 24(2)
- Quetiapine and acute liver failure
- Azithromycin and drug reaction with eosinophilia and systemic symptoms
- Clopidogrel and acquired hemophilia
- Summary of advisories
January 2014; 24(1)
- Vascular endothelial growth factor receptor inhibitors and thrombotic microangiopathy
- Incidents involving the combined use of Durepair Dura Regeneration Matrix with ancillary wound closure products
- Summary of advisories
October 2013; 23(4)
- Adverse reaction reports make a difference
- Summary of advisories
July 2013; 23(3)
- Oral fluoroquinolones and retinal detachment
- Adverse reaction and incident reporting-2012
- Summary of advisories
April 2013; 23(2)
- Intraocular lenses and the development of glistenings
- Exenatide: international reports of pancreatic cancer
- Quarterly Summary of health professional and consumer advisories
January 2013; 23(1)
- Pico-Salax (sodium picosulfate/magnesium citrate) and convulsions
- Risperidone and rhabdomyolysis independent of neuroleptic malignant syndrome
- Docetaxel and serious respiratory-related adverse reactions
- Case presentation: Ear drops containing peanut oil and suspected association with anaphylaxis
- Summary of advisories
October 2012; 22(4)
- Lyme disease test kits and limitations
- Antiandrogens and hepatotoxicity
- Case presentation: Thalomid and posterior reversible encephalopathy syndrome
- Summary of advisories
July 2012; 22(3)
- LigaSure vessel sealing system and torn vessels
- CARN is "going green"
- Adverse reaction and incident reporting -- 2011
- Summary of advisories
April 2012; 22(2)
- Minocycline: drug-induced lupus erythematosus and autoimmune hepatitis in adolescents
- Fentanyl and serotonin syndrome
- Summary of advisories
January 2012; 22(1)
- Second-generation antipsychotics and cardiometabolic adverse reactions in children and adolescents
- Prescription drugs and pediatric patients
- Canadian Paediatric Surveillance Program
- Adverse reaction reporting in children: update
- Adverse reaction reporting form
- Did you know? The Drug Safety and Effectiveness Network (DSEN) and pediatric projects
- Summary of advisories
October 2011; 21(4)
- Custom-Pak Ophthalmic Surgery Procedure Pack: contamination with foreign bodies and risk of related complications
- Case presentation: Dental/surgical rotary handpieces and patient burns
- CARN's 20th anniversary
- Did you know? Medical devices and incidents
- Summary of advisories
July 2011; 21(3)
- Proton pump inhibitors: hypomagnesemia accompanied by hypocalcemia and hypokalemia
- Adverse reaction and incident reporting -- 2010
- Case presentation: Floseal hemostatic matrix and suspected association with misinterpretation as recurrent malignant disease
- Risk communication information
- Summary of advisories
April 2011; 21(2)
- Fluticasone propionate and osteonecrosis
- Rosiglitazone-fenofibrate interaction: severe paradoxical decreased high-density lipoprotein cholesterol levels
- Varenicline and hyperglycemia in patients with diabetes
- Quinine sulfate and serious adverse reactions
- Summary of advisories
January 2011; 21(1)
- Clozapine and life-threatening gastrointestinal hypomotility
- Case presentation: Bio-Alcamid soft-tissue endoprosthesis and suspected association with late infection
- Natural health product identification in adverse reaction reports
- Summary of advisories
October 2010; 20(4)
- Statins and interstitial lung disease
- Potential interference of computed tomography(CT) scanning with electronic medical devices
- Case presentation: Red Bull Energy Drink and suspected association with seizure
- New consumer form for reporting adverse reactions
- Summary of advisories
July 2010; 20(3)
- Pregabalin (Lyrica): suicidal ideation and attempt
- Adverse incidents with injectable hyaluronic acid dermal fillers
- Oral iron supplements: skin reactions and other hypersensitivity reactions
- Summary of advisories
April 2010; 20(2)
- Leflunomide and peripheral neuropathy
- Adverse reaction and incident reporting - 2009
- Summary of advisories
January 2010; 20(1)
- Black cohosh products and liver toxicity: update
- Canada Vigilance Online Database
- Case presentation: Denture adhesive creams and neuropathy
- Summary of advisories
October 2009; 19(4)
- Intravenous immune globulin (IVIG): hemolytic reactions
- Antiviral medications and influenza A (H1N1): reporting adverse reactions
- Sildenafil (Revatio): medication incident
- Adverse reaction reporting form
- Summary of advisories
July 2009; 19(3)
- Montelukast (Singulair): psychiatric reactions
- Intravitreal injection of triamcinolone acetonide: ocular reactions
- Fentanyl transdermal patches and accidental child exposure
- Summary of advisories
April 2009; 19(2)
- Atypical antipsychotics and agranulocytosis
- Adverse reaction and incident reporting - 2008
- Announcement: Cough and cold products
- Case presentation: 5-Hour Energy drink and a cardiovascular adverse reaction
- Adverse reaction reporting form
- Summary of advisories
January 2009; 19(1)
- Local anesthetic infusion with pain pumps and chondrolysis
- Natural health products and adverse reactions: update
- Case presentation: Propolis and renal failure
- Summary of advisories
October 2008; 18(4)
- Botulinum toxin type A and distant toxin spread
- Case presentation: IVIG and transfusion-related acute lung injury
- Cesium chloride and ventricular arrhythmias
- Summary of advisories
July 2008; 18(3)
- Fentanyl transdermal patch and fatal adverse reactions
- Atomoxetine and suicidal behaviour: update
- Twinject auto-injector and device malfunctions
- Summary of advisories
April 2008; 18(2)
- Varenicline and serious psychiatric reactions
- Serious adverse reaction and medication incident
- Adverse reaction reporting - 2007
- Summary of advisories
January 2008; 18(1)
- IVIG: myocardial infarction and cerebrovascular and thrombotic adverse reactions
- Case presentation: NuvaRing and aortic thrombosis
- Canada Vigilance Program
- Evra: myocardial infarction and thromboembolic adverse reactions
- Summary of advisories
October 2007; 17(4)
- Gadolinium-containing agents: update on nephrogenic systemic fibrosis
- Sibutramine and cardiovascular adverse reactions
- Swedish Adjustable Gastric Band and erosion
- Summary of advisories
July 2007; 17(3)
- Benadryl Total: medication incident and stroke
- Rosiglitazone and parotid gland enlargement: update
- Adverse reaction reporting: education modules
- Case presentation: Norethindrone and decreased breast milk production
- Summary of advisories
April 2007; 17(2)
- Quetiapine: pancreatitis and thrombocytopenia
- Case presentation: Telithromycin and toxic epidermal necrolysis
- Bitter orange (synephrine): update on cardiovascular reactions
- Adverse reaction reporting - 2006
- Summary of advisories
January 2007; 17(1)
- Levofloxacin: dysglycemia and liver disorders
- Domperidone: heart rate and rhythm disorders
- Case presentation: Green tea extract and hepatotoxicity
- Summary of advisories
October 2006; 16(4)
- BioGlue: chronic inflammation and foreign-body reactions
- New tool for reporting adverse reactions
- Physician reporting of adverse reactions
- Case presentation: Atomoxetine and tics
- Summary of advisories
July 2006; 16(3)
- Adverse reactions in children: Why report?
- Case presentations:
- Extended-release methylphenidate withdrawal: priapism
- Iodoquinol: hypertensive encephalopathy and seizures
- Symposium on drug, food and natural health product interactions
- Summary of advisories
April 2006; 16(2)
- Tenofovir and NSAIDs: acute renal failure
- Adverse reaction reporting - 2005
- Isotretinoin: myocardial infarction, cerebrovascular and thromboembolic disorders
- Case presentation: Overnight orthokeratology and Acanthamoeba keratitis
- Regional Adverse Reaction Centres: relocation
- Summary of advisories
January 2006; 16(1)
- Oseltamivir and warfarin: increase in INR
- Levonorgestrel-releasing intrauterine system and uterine perforation
- Guidance document for industry
- Energy drinks
- Case presentation: Rosiglitazone: parotid gland enlargement
- Summary of advisories
October 2005; 15(4)
- Intrathecal baclofen: pump system incidents
- Statins and memory loss
- Chloral hydrate and potassium chloride: medication incident
- Case presentation: Ayurvedic medicines: lead contamination
- New MedEffect e-notice and Web site
- Summary of advisories
July 2005; 15(3)
- Transdermal fentanyl: abuse in adolescents
- Black cohosh: international reports of liver toxicity
- Rosiglitazone: decreased HDL cholesterol levels
- Ibuprofen: Stevens-Johnson syndrome
- New Regional Adverse Reaction Centres
- Case presentation: mefloquine with QT prolongation
- Summary of advisories
April 2005; 15(2)
- Hylan G-F 20: joint inflammation and pain
- Adverse reaction reporting - 2004
- Products derived from bees: serious adverse reactions
- Case presentation: rhabdomyolysis with clopidogrel, atorvastatin and cyclosporine
- Summary of advisories
January 2005; 15(1)
- Telithromycin and warfarin
- Linezolid and neuropathy
- Camphor and eucalyptus oils
- Adverse reaction reporting
- Natural weight loss product and myopathy
- Ceftriaxone and immune hemolytic anemia in children
- Case presentation: olanzapine and pulmonary embolism
- Summary of advisories
October 2004; 14(4)
- Transdermal fentanyl (Duragesic): respiratory arrest in adolescents
- Infliximab (Remicade) and etanercept (Enbrel): serious infections and tuberculosis
- Bitter orange (synephrine): cardiovascular reactions
- Case presentations:
- Ibutilide and torsades de pointes
- Tubersol and anaphylaxis
- Summary of advisories
July 2004; 14(3)
- Fluoroquinolones and warfarin: suspected interactions
- Suspected warfarin-cranberry juice interaction
- Case presentations:
- Tutoplast Dura graft and Creutzfeldt-Jakob disease
- Toxic shock syndrome and tampons
- Summary of advisories
April 2004; 14(2)
- Sterol and sterolin-containing products: hematologic adverse reactions
- Adverse reaction reporting - 2003
- Feasibility study of active surveillance of adverse reactions in children
- Public opinion survey on post-market surveillance
- Case presentation: clopidogrel
- Summary of advisories
January 2004; 14(1)
- Valdecoxib (Bextra™): severe cutaneous reactions
- Natural health products
- Case presentations:
- Ciprofloxacin
- Finasteride
- Drug Safety Information Workshop II Report
- Human growth hormone (somatropin): Prader-Willi syndrome
- Summary of advisories
October 2003; 13(4)
- Bisphosphonates and ocular disorders
- Fluticasone and adrenal suppression
- Adhesion prevention solutions in gynecological procedures
- Case presentation: intravenous immunoglobulins
- Summary of Advisories
- Insulin products
July 2003; 13(3)
- Gatifloxacin (Tequin™): hypoglycemia and hyperglycemia
- Serotonin syndrome
- Summary of advisories
- Case presentation: red yeast rice and rhabdomyolysis
April 2003; 13(2)
- Withdrawal reactions with paroxetine and other SSRIs
- Adverse reaction reporting - 2002
- Case presentation: divalproex
- Safe use of products containing acetaminophen
- Hormone replacement therapy
- Summary of advisories
January 2003; 13(1)
- Suspected hepatobiliary reactions to the newer antidepressants
- Convulsions and newer-generation antihistamines
- Drug Safety Information Workshop Report
- Case presentation: RespirActin
- Summary of advisories
October 2002; 12(4)
- Natural Health Products: adverse reactions
- Leflunomide (Arava): hematologic, hepatic and respiratory reactions
- Case Presentation: moxifloxacin
- Summary of Advisories
- Drugs and grapefruit: interactions
July 2002; 12(3)
- Pure red cell aplasia and Eprex
- Glitazones: update on adverse reactions
- Safety of human insulins
- Case presentation : Kava
- Summary of Advisories
April 2002; 12(2)
- Marketed Health Products Directorate
- Selective COX-2 inhibitors
- Summary of advisories
- Oral sodium phosphates solutions
- Case presentation
- Adverse reaction reporting - 2001
January 2002; 12(1)
- Statins: rhabdomyolysis and myopathy
- Alendronate: suspected pancreatitis
- HIV-associated lipodystrophy syndrome: overview and summary of case reports
- Summary of drug advisories
- Communiqué - Ibuprofen pediatric oral liquid: gastrointestinal bleeding
October 2001; 11(4)
- Antitubercular drugs: hepatobiliary reactions
- Electronic subscription to this Newsletter and drug advisories
- Health professional advisories
- Atypical antipsychotics: impaired glucose metabolism
- Communiqué - Brimonidine (Alphagan) ophthalmic drops: accidental ingestion
July 2001; 11(3)
- Drug advisories now available on the Web
- Miconazole-warfarin interaction: increased INR
- New toll-free numbers to report ADRs
- Rosiglitazone (Avandia): hepatic, cardiac and hematological reactions
- Adverse drug reaction reporting - 2000: Part 2
- Communiqué
- Orlistat (Xenical) interaction with coumarin derivatives: increased INR
- Azithromycin (Zithromax): myocardial infarction
- Drugs of Current Interest
April 2001; 11(2)
- Adverse drug reaction reporting - 2000: Part 1
- Antiparkinsonian drugs and "sleep attacks"
- Rofecoxib (Vioxx): a year in review
- Communiqué - Warfarin and glucosamine: interaction
- Drugs of Current Interest
January 2001; 11(1)
- Thioridazine (Mellaril) and mesoridazine (Serentil): prolongation of the QTc interval
- Clopidogrel (Plavix): hematological reactions
- Gentamicin ear drops and ototoxicity: update
- Drugs of Current Interest
October 2000; 10(4)
- New influenza drugs: unexpected serious reactions
- Intravenous RhO [D] immune globulin [human]: suspected hemolytic/renal adverse reactions
- Abboject® Unit-of-Use Syringe: reports of malfunction
- Communiqué
- Glucosamine sulfate: hyperglycemia
- Ketotifen (Zaditen®): sleep apnea
- Diclofenac (Voltaren Ophtha®) and ketorolac tromethamine (Acular®): corneal ulceration
- Drugs of Current Interest
July 2000; 10(3)
- St. John's wort: harmful drug interaction
- Olanzapine (Zyprexa): suspected serious reactions
- Sildenafil (Viagra): cardiac risks
- New Bureau Name
- Communiqué
- Citalopram (Celexa) and clarithromycin (Biaxin): interaction
- Itraconazole (Sporanox): serum sickness-like disorder
- Drugs of Current Interest
April 2000; 10(2)
- Adverse drug reaction reporting - 1999
- Celecoxib (Celebrex): 1 year later
- Correction - ticlopidine
- Communiqué - orlistat (Xenical): pancreatitis
- Drugs of Current Interest
January 2000; 10(1)
- Cisapride (Prepulsid): interactions
- Pemoline (Cylert): market withdrawal
- Bupropion (Zyban): update
- Communiqué
- HIV protease inhibitors: paronychia
- Gingko biloba: bleeding disorders
- Drugs of Current Interest
October 1999; 9(4)
- Serious hematologic reactions associated with ticlopidine - update
- Leukotriene receptor antagonists: suspected adverse reactions
- Communiqué - Ropinirole (Requip): sleep disorder
July 1999; 9(3)
- Alteplase (Activase rt-PA) for acute ischemic stroke
- Abciximab (ReoPro): risk of acute thrombocytopenia
- Nefazodone (Serzone) and hepatotoxicity
- Communiqué - Amlodipine (Norvasc): hearing loss
April 1999; 9(2)
- Bupropion (Zyban): suspected adverse reactions
- 1998 ADR Statistics
- Updates: immune globulin IV products, tolcapone (Tasmar)
- Communiqué - Olanzapine (Zyprexa): priapism
January 1999; 9(1)
- Isotretinoin and depression
- Low-dose ASA and GI Bleeding
- Guidelines for reporting ADRs
- Communiqué - azithromycin, pentoxifylline, sertraline and carbamazepine: interaction
October 1998; 8(4)
- Recent News About Drug Risks
- New Ontario Regional ADR Centre
- Discontinuation Reactions Associated With SSRIs
- Communiqué - amantadine and warfarin, pantoprazole
July 1998; 8(3)
- Quality Information in Spontaneous Reports
- Donepezil: Suspected Adverse Reactions
- Olanzapine: Hematological Reactions
- Communiqué - valproic acid, cefaclor, latanoprost, protease inhibitors
April 1998; 8(2)
- Alendronate-induced esophagitis
- 1997 ADR statistics
- Communiqué - dorzolamide hydrochloride, hydroxychloroquine sulfate, torvastatin calcium, risperidone, venlafaxine hydrochloride
January 1998; 8(1)
- Drugs: QT interval prolongation and torsades de pointes
- Ciprofloxacin use in epileptic patients taking phenytoin
- Appetite suppressants - update
- Communiqué - vigabatrin, mefloquine, lamotrigine
October 1997; 7(4)
- Calcium-channel blockers
- Azithromycin - severe iatrogenic hepatitis
- Newsletter survey results
- Communiqué - protease inhibitors, vigabatrin, terconazole, Fen-phen, heparin, paroxetine
July 1997; 7(3)
- ACE inhibitors and bronchospasm
- Interferon beta-1b
- Radiopharmaceuticals
- New Expert Advisory Committee on Pharmacovigilance
April 1997; 7(2)
- Adverse drug reaction reporting - 1996
- Potential abuse of butorphanol nasal spray
- Aminoglycoside ear drops and ototoxicity
January 1997; 7(1)
- Primary pulmonary hypertension and appetite suppressants
- HIV protease inhibitors and increased bleeding in hemophilia?
- Erythema multiforme and nifedipine
- Congenital anomalies and fluconazole
October 1996; 6(4)
- Cefaclor-associated serum sickness-like reaction
- Newsletter Assessment - Questionnaire
July 1996; 6(3)
- Cisapride: Arrhythmia Awareness
- Midazolam: A Wake-Up Call
- Clarithromycin: Tooth Discolouration and Smell Alteration
April 1996; 6(2)
- Metformin: Lactic Acidosis
- Nefazodone: ADR Profile
- 1995 Statistics ADR or Product Fault?
January 1996; 6(1)
- Cotrimoxazole
- Nicotine Patches and exercise
- Terbinafine - hepatobiliary reactions
- SSRIs - hyponatremia
October 1995; 5(4)
- Update: Fertility Drugs
- Propofol: Convulsions
- Contraindications: Dinoprostone
- Vaginal Gel
- DOCI List
July 1995; 5(3)
- Reporting Adverse Drug Reactions
- Lamotrigine (Lamictal): rashes
- Drug Names: confusion from two fronts
- Tiaprofenic Acid: cystitis
- Ticlopidine: revisited
- DOCI List
April 1995; 5(2)
- Zidovudine: Benefits of use during pregnancy
- Serevent®: Patient warnings must be stressed
- Fluoroquinolones: Tendonitis
- Topical Antifungals: Recent switch to over-the-counter
- Phenazopyridine: Hemolytic anemia
January 1995; 5(1)
- Risperidone and EPS Sumatriptan and migraine exacerbation
- Bromocriptine
- Fertility drug awareness
- New regional centre for Quebec
October 1994; 4(3)
- Regional Centres
- New Drugs - Serzone, Neurontin, Sabril
- Drugs of current interest
July 1994; 4(2)
- Editorial Note
- Terbinafine Herbal preparations
March 1994; 4(1)
- Rhabdomyolysis and HMG-CoA
- Reductase Inhibitors
- Antidepressants and Suicide
- Help Wanted: Risperdal
November 1993; 3(2)
- Ticlopidine HCl - Hematological and Liver Effects
- H1-Antihistamines - Cardiotoxic Effects
August 1993; 3(1)
- ACE Inhibitors: Renal Effects
- Sumatriptan Succinate: Chest Pain
- Nicotine Patches: Update / Inadvertent Exposure
April 1992; 2(1)
- ADR Program, 1991 Annual Report
- Case Report: Drug Interactions with Omeprazole
- Vasospasm with B-Blockers
- GI Bleeding with Toradol®
August 1991; 1(2)
- PPSP Workshop Minocycline - Case reports of severe liver and renal reactions
- ADRs in the Elderly Ciprofloxacin - ADR profile Diclofenac - Hepatic reactions
January 1991; 1(1)
- Saskatchewan ADR Pilot Project
- The WHO Connection Working Group on ADR Assessment
Page details
- Date modified: